Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
TUSTIN, Calif., March 09, 2017 -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is payable on April 3, 2017 to holders of record at the close of business on March 20, 2017.
The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2017 through March 31, 2017. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
